Understanding the Critical Disposition Pathways of Statins to Assess Drug–Drug Interaction Risk During Drug Development: It's Not Just About OATP1B1

Transporter-Mediated Drug–Drug Interactions Involving OATP Substrates: Predictions Based on In Vitro Inhibition Studies

(2012) K Yoshida et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

Predicting Drug Interaction Potential With a Physiologically Based Pharmacokinetic Model: A Case Study of Telithromycin, a Time-Dependent CYP3A Inhibitor

(2012) Md L T Vieira et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

Prediction of the in vivo OATP1B1-mediated drug–drug interaction potential of an investigational drug against a range of statins

(2012) Pradeep Sharma et al.   EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES

Pitavastatin: An overview

(2011) Yasushi Saito   ATHEROSCLEROSIS SUPPLEMENTS

Evaluation of CYP2C8 Inhibition In Vitro: Utility of Montelukast as a Selective CYP2C8 Probe Substrate

(2011) B. M. VandenBrink et al.   DRUG METABOLISM AND DISPOSITION

Kinetic Characterization of Rat Hepatic Uptake of 16 Actively Transported Drugs

(2011) Y. Yabe et al.   DRUG METABOLISM AND DISPOSITION

Prediction of the Overall Renal Tubular Secretion and Hepatic Clearance of Anionic Drugs and a Renal Drug-Drug Interaction Involving Organic Anion Transporter 3 in Humans by In Vitro Uptake Experiments

(2011) T. Watanabe et al.   DRUG METABOLISM AND DISPOSITION

Statin-induced myopathy: a review and update

(2011) Thura T Abd et al.   Expert Opinion On Drug Safety

Weighing the Benefits of High-Dose Simvastatin against the Risk of Myopathy

(2011) Amy Egan et al.   NEW ENGLAND JOURNAL OF MEDICINE

The evolution of the OATP hepatic uptake transport protein family in DMPK sciences: from obscure liver transporters to key determinants of hepatobiliary clearance

(2011) Katherine S. Fenner et al.   XENOBIOTICA

The search beyond statins

(2010) Melinda Wenner Moyer   NATURE MEDICINE

Transporter Pharmacogenetics and Statin Toxicity

(2009) M Niemi   CLINICAL PHARMACOLOGY & THERAPEUTICS

ABCG2 Polymorphism Markedly Affects the Pharmacokinetics of Atorvastatin and Rosuvastatin

(2009) J E Keskitalo et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

Physiologically Based Predictions of the Impact of Inhibition of Intestinal and Hepatic Metabolism on Human Pharmacokinetics of CYP3A Substrates

(2009) Frederique Fenneteau et al.   JOURNAL OF PHARMACEUTICAL SCIENCES

The SLCO1B1*5Genetic Variant Is Associated With Statin-Induced Side Effects

(2009) Deepak Voora et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

Different effects of theABCG2c.421C>A SNP on the pharmacokinetics of fluvastatin, pravastatin and simvastatin

(2009) Jenni E Keskitalo et al.   PHARMACOGENOMICS

Relationship between Drug/Metabolite Exposure and Impairment of Excretory Transport Function

(2008) M. J. Zamek-Gliszczynski et al.   DRUG METABOLISM AND DISPOSITION

Involvement of Multiple Transporters in the Hepatobiliary Transport of Rosuvastatin

(2008) S. Kitamura et al.   DRUG METABOLISM AND DISPOSITION

Peptide prodrugs: Improved oral absorption of lopinavir, a HIV protease inhibitor

(2008) Sheetal Agarwal et al.   INTERNATIONAL JOURNAL OF PHARMACEUTICS

SLCO1B1Variants and Statin-Induced Myopathy — A Genomewide Study

(2008)   NEW ENGLAND JOURNAL OF MEDICINE

Pharmacokinetics of the CYP 3A Substrate Simvastatin following Administration of Delayed Versus Immediate Release Oral Dosage Forms

(2008) Marija Tubic-Grozdanis et al.   PHARMACEUTICAL RESEARCH

The effect of SLCO1B1*15 on the disposition of pravastatin and pitavastatin is substrate dependent: the contribution of transporting activity changes by SLCO1B1*15

(2008) Jian Wei Deng et al.   Pharmacogenetics and Genomics